Whereas afatinib has received an extension of the FDA label for patients with NSCLC bearing L861Q, G719X and S768I mutations, no specific approval for patients with atypical EGFR currently exists in Europe. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.